M

MoonLake Immunotherapeutics
NASDAQ:MLTX

Watchlist Manager
MoonLake Immunotherapeutics
NASDAQ:MLTX
Watchlist
Price: 11.17 USD -0.18% Market Closed
Market Cap: 803.1m USD

MoonLake Immunotherapeutics
EPS (Diluted)

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

MoonLake Immunotherapeutics
EPS (Diluted) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company EPS (Diluted) CAGR 3Y CAGR 5Y CAGR 10Y
M
MoonLake Immunotherapeutics
NASDAQ:MLTX
EPS (Diluted)
-$1
CAGR 3-Years
-9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
EPS (Diluted)
-$1
CAGR 3-Years
11%
CAGR 5-Years
13%
CAGR 10-Years
N/A
AC Immune SA
NASDAQ:ACIU
EPS (Diluted)
CHf0
CAGR 3-Years
6%
CAGR 5-Years
3%
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
EPS (Diluted)
-$5
CAGR 3-Years
15%
CAGR 5-Years
-12%
CAGR 10-Years
N/A
Idorsia Ltd
SIX:IDIA
EPS (Diluted)
CHf0
CAGR 3-Years
53%
CAGR 5-Years
30%
CAGR 10-Years
N/A
Xlife Sciences AG
SIX:XLS
EPS (Diluted)
CHf4
CAGR 3-Years
-19%
CAGR 5-Years
73%
CAGR 10-Years
N/A
No Stocks Found

MoonLake Immunotherapeutics
Glance View

Market Cap
803.1m USD
Industry
N/A

MoonLake Immunotherapeutics is carving a distinct niche for itself in the biopharmaceutical sector, honing its expertise in the development of nanobody-based therapies. Nanobodies are a novel type of antibody derived from the unique immune systems of camelids like alpacas. These smaller, robust antibodies have the potential to engage epitopes that are not accessible to traditional antibodies, offering a strategic advantage in targeting complex immunological pathways. MoonLake is directing this technology toward treating inflammatory diseases, with a particular focus on dermatological and rheumatological conditions. By concentrating on these chronic and often debilitating diseases, the company aims to meet pressing medical needs that have been underserved by current therapies, ultimately improving patient outcomes through innovative approaches. The financial backbone of MoonLake Immunotherapeutics hinges on leveraging partnerships and collaborations with other pharmaceutical giants. By entering into strategic alliances, they gain access to proprietary research, expansive distribution channels, and the capital necessary to propel their mission forward. This collaborative model not only mitigates the inherent risks in drug development but also aids in monetizing their pipeline through milestone payments, royalties, and profit-sharing arrangements as products successfully reach commercialization stages. By maintaining a clear focus on the validation and advancement of their lead assets, such as the SLK-based therapies, MoonLake is evolving as a prominent player in the biopharma landscape, all while optimizing both scientific innovations and shareholder value.

MLTX Intrinsic Value
Not Available
M

See Also

What is MoonLake Immunotherapeutics's EPS (Diluted)?
EPS (Diluted)
-1.9 USD

Based on the financial report for Dec 31, 2024, MoonLake Immunotherapeutics's EPS (Diluted) amounts to -1.9 USD.

What is MoonLake Immunotherapeutics's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
-9%

Over the last year, the EPS (Diluted) growth was -159%. The average annual EPS (Diluted) growth rates for MoonLake Immunotherapeutics have been -9% over the past three years .

Back to Top